Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-12-22
- Last Posted Date
- 2017-04-14
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03000634
Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Grade 3a Follicular LymphomaRecurrent Marginal Zone LymphomaB-Cell Lymphoma, UnspecifiedGrade 2 Follicular LymphomaRefractory Burkitt LymphomaRefractory Diffuse Large B-Cell LymphomaTransformed Recurrent Non-Hodgkin LymphomaRecurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular Lymphoma
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Beth Christian
- Target Recruit Count
- 22
- Registration Number
- NCT02992522
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Sun Yat-sen University
- Registration Number
- NCT02986451
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, GuangZhou, Guangdong, China
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2018-01-19
- Target Recruit Count
- 34
- Registration Number
- NCT02983097
- Locations
- 🇩🇪
LMU Klinikum München-Großhadern, München, Germany
🇩🇪Diakonie Krankenhaus Bremen, Bremen, Germany
🇩🇪Universitätsklinikum Heidelberg, Heidelberg, Germany
SPI-directed Analgesia for Vitreoretinal Surgeries
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Medical University of Silesia
- Target Recruit Count
- 176
- Registration Number
- NCT02973581
- Locations
- 🇵🇱
Medical University of Silesia, Sosnowiec, Silesia, Poland
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 47
- Registration Number
- NCT02969837
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02963610
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02954406
- Locations
- 🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇺🇸Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute, West Hollywood, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Tucson, Arizona, United States
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
- Conditions
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT02951351
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.